Search

Displaying results 1141 - 1150 of 8170 in total
  1. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. … [A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart

    Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  2. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: Urin D/S, Uretron D/S
  3. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  4. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  5. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732 … Potassium bitartrate has a long history of medical use as a laxative administered as a rectal suppository and is an approved third-class OTC drug in Japan.

  6. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    [L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate. … [L4274] Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who

  7. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    [L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-?-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-?-oxo-1-piperidinepropanenitrile, (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
  8. Drug

    Anidulafungin

    go.drugbank.com/drugs/DB00362
    Approved

    Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.

  9. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]

    Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Norethisterone

    go.drugbank.com/drugs/DB00717
    ApprovedInvestigational

    L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an

    International brands: Mini-PECategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates